Asthma Control Questionnaire
- Introduced by
- Elizabeth F. Juniper, McMaster University
- Year
- 1999
- Type
- Self-report questionnaire
- Family
- asthma-control
What does it do?
The ACQ is a 7-item self-report questionnaire developed by Juniper and colleagues at McMaster University in 1999 to assess the degree of asthma control in the previous one to two weeks.
Unlike generic respiratory tools, the ACQ measures symptom-based control and rescue medication use, providing a simple yet psychometrically sound method for evaluating treatment efficacy. It is widely adopted in clinical trials, guideline-driven care, and routine asthma management to guide therapy titration and assess treatment response.
The intuition behind the method
The ACQ was designed to answer a straightforward clinical question: Is the patient's asthma adequately controlled? Rather than measuring quality of life or functional limitation per se, it focuses on objective control indicators that inform treatment decisions. The five symptom questions capture nocturnal awakening, morning symptoms, activity limitation, and breathlessness frequency—key markers of inadequate control. Two additional questions measure use of rescue bronchodilator (an objective proxy for breakthrough symptoms) and, in the longer version, baseline FEV₁. This dual symptom + objective measure approach balances patient perception with objective clinical markers.
History
Juniper and colleagues developed the ACQ at McMaster University and first published it in 1999 in the European Respiratory Journal. The original validation demonstrated superior responsiveness to change compared to generic measures in asthma clinical trials. Shorter versions (ACQ-5, ACQ-6) were later introduced to reduce burden in routine care. The ACQ has been translated into numerous languages and is now embedded in many asthma management guidelines, including Global Initiative for Asthma (GINA) recommendations.
When to use it
The ACQ is indicated for patients with persistent asthma (intermittent asthma may show floor effects). It is ideal in clinical trials to measure treatment response, in primary care and specialty asthma clinics to guide step-up/step-down decisions, and in chronic disease management programs to assess control trajectory. The ACQ is less useful for acute asthma exacerbation assessment or in patients with asthma exacerbations occurring <1 week prior (recent events may artificially elevate scores).
Limitations and considerations
- Recall period dependency: Assesses 'past 1–2 weeks'; longer-term asthma control patterns may be obscured
- Floor effects in controlled asthma: Highly controlled patients may consistently score ≤0.5, leaving limited room to detect further improvement
- FEV₁ requirement in ACQ-7: The standard version includes baseline spirometry; ACQ-6 (without FEV₁) may be preferable when spirometry is unavailable
Source conditions do not replace independent scientific review or validation by an analysis engine.
Strengths
- Brevity: 7 items require only 2–3 minutes, enhancing feasibility in busy clinical settings
- Objective and subjective hybrid: Combines symptom reports with rescue medication use (objective proxy for control), reducing pure self-report bias
- Well-established cutoffs: Clear threshold interpretations (≤0.75 = controlled) facilitate straightforward clinical decisions
- Responsive to change: Sensitive to treatment effects; changes of 0.5 units reliably signal clinically meaningful improvement or deterioration
Applications
- Clinical trials: Primary or secondary endpoint for evaluating new asthma medications or interventions; sensitive to treatment-induced control changes
- Primary care asthma monitoring: Point-of-care tool to screen for inadequate control and guide step-up or maintenance decisions at regular visits
- Specialist asthma clinics: Baseline assessment and longitudinal tracking in patients with difficult-to-control or severe asthma to evaluate complex therapy regimens
- Asthma action plan guidance: Objectively inform when patients should escalate or de-escalate rescue medication and when to seek urgent care
How it works
How it works
The ACQ-7 comprises five symptom items and two additional items (rescue medication use and baseline pulmonary function; in some versions, the latter is clinician-measured FEV₁ rather than patient-reported). Each item is scored on a 0–6 scale, with anchors varying: 'not at all' (0) to 'all of the time' (6) for symptom items, and frequency anchors for rescue use. The questionnaire is self-completed, requiring approximately 2–3 minutes. A shorter version (ACQ-6) and the original 5-item symptom-only variant (ACQ-5) are also available.
Formula
Respondent completes 7-item questionnaire with mixed scoring anchors
The ACQ-7 mean score is calculated as the average of all seven items, yielding a continuous 0–6 scale. A mean score ≤0.75 indicates well-controlled asthma; a mean score >1.5 indicates inadequately controlled asthma. Scores between 0.75 and 1.5 represent intermediate control. Some versions use cutoff thresholds: ≤1.0 = controlled, >1.0 = not controlled. The change in score is also clinically important; a reduction of ≥0.5 units reflects meaningful improvement.
Formula
Each item scored 0–6; mean calculated across all items
ACQ-7 interpretation: mean ≤0.75 = well-controlled asthma (minimal daytime symptoms, rare nighttime awakening, no activity limitation), mean 0.75–1.5 = intermediate control (occasional symptoms or limitation), mean >1.5 = poorly controlled asthma (frequent symptoms, regular rescue use, activity restriction). Clinical decision: patients with scores >1.5 warrant treatment escalation; those with scores ≤0.75 may be candidates for step-down therapy. The ACQ tracks month-to-month control and informs real-time treatment adjustment.
Formula
Mean score interpreted as degree of asthma control
Common pitfalls
- Ignoring recent exacerbations: A single exacerbation <1 week prior can elevate the ACQ score above actual baseline control; always contextualize within recent event history
- Misapplying control thresholds: The ≤0.75 'well-controlled' cutoff is validated for group-level decisions in trials; individual clinical judgment remains essential
- Conflating control with symptom absence: Some patients may have low baseline symptoms due to avoidance behavior (e.g., limiting activity) rather than true control; assess objectively alongside symptom reports
Frequently asked questions
What is the difference between ACQ-7, ACQ-6, and ACQ-5?
ACQ-7 includes all five symptoms plus rescue medication use plus baseline FEV₁ (clinician-measured). ACQ-6 omits FEV₁ (patient or clinician-reported). ACQ-5 includes only the five symptom items. All three have valid cutoffs; choice depends on whether spirometry is available and time constraints.
A patient scores 0.9 on the ACQ; is their asthma controlled?
A score of 0.9 falls in the 'intermediate control' range (0.75–1.5). While not in the 'well-controlled' range (≤0.75), it does not meet the threshold for poor control (>1.5). Clinical context matters: if baseline was >1.5, this represents improvement; if the goal is tighter control, treatment adjustment may be warranted.
How sensitive is the ACQ to seasonal or irregular asthma?
The ACQ's 1–2-week recall period captures recent control but may not reflect year-round patterns in seasonal asthma. Repeat measurements across seasons or extended recall versions may better characterize seasonal patterns.
Should I use ACQ or a generic questionnaire like SF-36 for asthma?
Use ACQ for asthma control monitoring and treatment decisions. ACQ is more sensitive and specific to asthma control. Use generic tools like SF-36 when broader health-related quality of life is relevant (e.g., asthma impact on work/social function) alongside ACQ for a complete picture.
Related methods
Sources
Juniper, E. F., O'Byrne, P. M., Guyatt, G. H., Ferrie, P. J., & King, D. R. (1999). Development and validation of a questionnaire to measure asthma control. European Respiratory Journal, 14(4), 902-907.
Open DOI referenceCopied.Juniper, E. F., Svensson, K., Mörk, A. C., & Ståhl, E. (2005). Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respiratory Medicine, 99(5), 553-558.
Open DOI referenceCopied.